Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akers Biosciences, Inc.    AKER

AKERS BIOSCIENCES, INC.

(AKER)
  Report
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

11/18/2020 | 09:32am EST

Item 8.01 Other Events.

On November 17, 2020, Akers Biosciences, Inc. (the "Company") closed a previously announced private placement of 9,765,933 shares of its common stock and warrants to purchase 9,765,933 shares of its common stock resulting in aggregate gross proceeds to the Company of approximately $18.1 million (the "Private Placement"). In connection with the Private Placement and pursuant to a previously reported engagement letter entered into by and among the Company and Katalyst Securities LLC (the "Placement Agent"), the Company also issued the Placement Agent a warrant to purchase up to 390,368 shares of the Company's common stock at an exercise price of $1.85 (the "Placement Agent Warrant"). The Placement Agent Warrant will be exercisable at any time and from time to time, in whole or in part, following the date of issuance and for a term of five and a half years.

A form of the Placement Agent Warrant is attached hereto as Exhibit 4.1 and is incorporated herein by reference. The description of the Placement Agent Warrant herein does not purport to be complete and is qualified in its entirety by reference to Exhibit 4.1.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit Number               Description
4.1                Form of Placement Agent Warrant

© Edgar Online, source Glimpses

All news about AKERS BIOSCIENCES, INC.
01/25AKERS BIOSCIENCES : Submission of Matters to a Vote of Security Holders (form 8-..
AQ
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : ' Proposed Merger Partner MyMD Pharmaceuticals Announces Iss..
BU
2020AKERS BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form ..
AQ
2020REMINDER : Akers Biosciences Schedules Conference Call to Discuss Merger with My..
BU
2020AKERS BIOSCIENCES INVESTOR ALERT BY : Kahn Swick & Foti, LLC Investigates Merge..
BU
2020AKERS BIOSCIENCES : Management's Discussion and Analysis of Financial Condition ..
AQ
2020AKERS BIOSCIENCES, INC. : Other Events (form 8-K)
AQ
More news
Financials (USD)
Sales 2019 1,58 M - -
Net income 2019 -3,89 M - -
Net cash 2019 9,68 M - -
P/E ratio 2019 -0,50x
Yield 2019 -
Capitalization 25,1 M 25,1 M -
EV / Sales 2018 5,19x
EV / Sales 2019 -3,83x
Nbr of Employees 12
Free-Float 84,1%
Chart AKERS BIOSCIENCES, INC.
Duration : Period :
Akers Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKERS BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Managers and Directors
NameTitle
Christopher C. Schreiber President & Chief Executive Officer
Joshua Nathaniel Silverman Chairman
Stuart Benson Chief Financial Officer
Bill Joe White Independent Non-Executive Director
Robert C. Schroeder Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
AKERS BIOSCIENCES, INC.42.21%25
ABBOTT LABORATORIES4.78%196 561
MEDTRONIC PLC-0.20%157 350
BECTON, DICKINSON AND COMPANY4.00%75 691
HOYA CORPORATION-3.92%49 122
ALIGN TECHNOLOGY, INC.0.95%42 537